Mogrol
Based on 2 publication(s) in Google Scholar
Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.76%
- CAS No.: 88930-15-8
- Formule: C30H52O4
- Masse moléculaire:476.73
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-N2312R
Mogrol (Standard)STAT Inhibitor -
HY-50662
A-769662AMPK Activator -
HY-19696
TauroursodeoxycholateEndoplasmic Reticulum Stress Inhibitor -
HY-50846
SCH772984ERK1/2 Inhibitor -
HY-12275
FR 180204ERK Inhibitor -
HY-19696R
Tauroursodeoxycholate (Standard)Endoplasmic Reticulum Stress Inhibitor -
HY-10579
PluripotinERK1 and RasGAP Dual Inhibitor -
HY-N6257
CafestolERK2 Inhibitor -
HY-W001174
2,5-Dihydroxyacetophenone -
HY-19696B
Tauroursodeoxycholate dihydrateTaurine Conjugate Of Ursodeoxycholic Acid -
HY-N2283
DeltoninEndogenous Metabolite -
HY-18932
DEL-22379ERK Dimerization Inhibitor
Publications Citing Use of MedChemExpress (MCE) Mogrol
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
IF
-
Flow Cytometry
-
WB
-
RT-PCR
Activité biologique
Description
IC50 & Target
[1]|
ERK1 |
ERK2 |
STAT3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
27.78 μM
Compound: Mogrol
|
Antiproliferative activity against human A549 cells assessed as reduction in cell growth by CCK8 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell growth by CCK8 assay
|
[PMID: 33964443] |
| A549 | IC50 |
28.56 μM
Compound: Mogrol
|
Antiproliferative activity against human A549 cells
Antiproliferative activity against human A549 cells
|
[PMID: 35944853] |
| HepG2 | EC50 |
3 μM
Compound: Mogrol
|
Allosteric activation of AMPK alpha2/beta1/gamma1 in human HepG2 cells by scintillation proximity assay
Allosteric activation of AMPK alpha2/beta1/gamma1 in human HepG2 cells by scintillation proximity assay
|
[PMID: 31744674] |
| NCI-H1299 | IC50 |
>100 μM
Compound: Mogrol
|
Antiproliferative activity against human NCI-H1299 cells
Antiproliferative activity against human NCI-H1299 cells
|
[PMID: 35944853] |
| NCI-H1975 | IC50 |
87.14 μM
Compound: Mogrol
|
Antiproliferative activity against human NCI-H1975 cells
Antiproliferative activity against human NCI-H1975 cells
|
[PMID: 35944853] |
| NCI-H460 | IC50 |
>100 μM
Compound: Mogrol
|
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth by CCK8 assay
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth by CCK8 assay
|
[PMID: 33964443] |
| NCI-H460 | IC50 |
>100 μM
Compound: Mogrol
|
Antiproliferative activity against human NCI-H460 cells
Antiproliferative activity against human NCI-H460 cells
|
[PMID: 35944853] |
In Vitro
Mogrol (0-250 μM) significantly and dose- and time-dependently inhibits K562 cell growth and increases the number of apoptotic cells. Mogrol (0, 10, 100, and 250 μM) induces G1 phase cell cycle arrest in K562 cells. Treatment with mogrol significantly decreases ERK phosphorylation as compared to control cells, whereas total ERK protein is not affected. Mogrol dose-dependently induces growth arrest in G0/G1 phase of the cell cycle. Mogrol significantly and dose-dependently enhances p21 protein expression in K562 cells[1]. Mogrol significantly represses the increase in cellular TG levels induced by differentiation stimuli, and suppresses TG accumulation at micromolar levels, with a statistically significant suppression observed above 10 μM. Mogrol suppresses adipogenesis in 3T3-L1 cells at concentrations that does not affect cell viability. Mogrol suppresses adipogenesis through at least two different mechanisms, increasing AMPK phosphorylation and repressing the activation of CREB[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Chemical Information
-
CAS No. 88930-15-8
-
Appearance Solid
-
Masse moléculaire 476.73
-
Formule C30H52O4
-
Color White to off-white
-
SMILES
CC1(C)[C@@H](O)CC[C@@]2([H])[C@]3(C)[C@H](O)C[C@]4(C)[C@@H]([C@H](C)CC[C@@H](O)C(C)(O)C)CC[C@](C)4[C@]3([H])CC=C12
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
A polycistronic system for multiplexed and precalibrated expression of multigene pathways in fungi. [Abstract]2023 Jul 17;14(1):4267. PMID: 37460548 -
Drug Des Devel Ther
Mogrol Regulates the Expression of ATPase Na+/K+ Transport Subunit 3, Inhibits Cardiomyocyte Apoptosis, and Plays a Protective Role Against Myocardial Infarction. [Abstract]2025 Mar 2:19:1489-1502. PMID: 40051467
Mogrol purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2025 Mar 2:19:1489-1502. [Abstract]
CCK-8 detection of changes in cell viability of AC16 cells after treatment with different concentrations of Mogrol (6.25, 12.5, 25, 50, 100, 200 μM) for 48 h.
Mogrol purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2025 Mar 2:19:1489-1502. [Abstract]
EDU staining to observe the effect of Mogrol pretreatment on the proliferation of AC16 cells under hypoxia.
Mogrol purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2025 Mar 2:19:1489-1502. [Abstract]
Flow double staining to detect changes in cardiomyocyte apoptosis after Mogrol (50 μM) treatment.
Mogrol purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2025 Mar 2:19:1489-1502. [Abstract]
Western blotting was performed to detect changes in the expression of ATP1A3 and apoptosis-related proteins Bax, Bcl-2, and cleaved-caspase-3 in myocardial tissues after Mogrol (50 μM) treatment.
Mogrol purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2025 Mar 2:19:1489-1502. [Abstract]
Changes in ATP1A3 mRNA expression in cardiomyocytes after Mogrol (50 μM) treatment.
Solvant et solubilité
In Vitro:
DMSO : 50 mg/mL (104.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0976 mL | 10.4881 mL | 20.9762 mL | 52.4406 mL |
| 5 mM | 0.4195 mL | 2.0976 mL | 4.1952 mL | 10.4881 mL | |
| 10 mM | 0.2098 mL | 1.0488 mL | 2.0976 mL | 5.2441 mL | |
| 15 mM | 0.1398 mL | 0.6992 mL | 1.3984 mL | 3.4960 mL | |
| 20 mM | 0.1049 mL | 0.5244 mL | 1.0488 mL | 2.6220 mL | |
| 25 mM | 0.0839 mL | 0.4195 mL | 0.8390 mL | 2.0976 mL | |
| 30 mM | 0.0699 mL | 0.3496 mL | 0.6992 mL | 1.7480 mL | |
| 40 mM | 0.0524 mL | 0.2622 mL | 0.5244 mL | 1.3110 mL | |
| 50 mM | 0.0420 mL | 0.2098 mL | 0.4195 mL | 1.0488 mL | |
| 60 mM | 0.0350 mL | 0.1748 mL | 0.3496 mL | 0.8740 mL | |
| 80 mM | 0.0262 mL | 0.1311 mL | 0.2622 mL | 0.6555 mL | |
| 100 mM | 0.0210 mL | 0.1049 mL | 0.2098 mL | 0.5244 mL |
Mogrol Related Classifications
HY-N2312 Related Classifications
Powered by Bioz